AI Can Make a Difference on the Factory Floor If Biopharma Invests

Artificial intelligence has been making a difference in the discovery lab for a decade. Recently, consulting group BCG suggested that AI played a pivotal role in the identification of more than 150 current drug candidates, 15 of which are in trials. And, according to a separate analysis by Deloitte, AI approaches have also been used in areas like clinical trials, supply chain management, and commercial launch. Instances of AI use in drug production are few and far between. And this is a missed opportunity, according to Kiefer Eaton, from industrial artificial intelligence developer Basetwo AI, particularly because drug makers already have many of the elements they need to benefit from AI. "AI has been widely adopted for drug development and has recently seen a lot of growth for commercial pharmaceutical activities. However, biomanufacturing remains underserved despite the plethora of data to leverage," he says.